mk-1942
Treatment Resistant Depression
Merck Sharp & Dohme LLCPhase 2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 27/ 100
- Competitive Position
- 81/ 100
Competitive context
235 Active assets in the Treatment Resistant Depression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal Johns Hopkins University | Phase 4 | BBB |
Zelapar Corium Innovations, Inc. | Phase 4 | BBB |
S-Ketamine Janssen Research & Development, LLC | Phase 4 | BBB |
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
Opc-34712 Nova Scotia Health Authority | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
mk-1942 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →